Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 5 |
2024 | 2 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future.
J Clin Med. 2023 Mar 11;12(6):2188. doi: 10.3390/jcm12062188.
J Clin Med. 2023.
PMID: 36983189
Free PMC article.
Review.
Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significance.
Giuffrida G, Markovic U, Condorelli A, Duminuco A, Calafiore V, Conticello C, Romano A, Grasso S, Riccobene C, Ragusa MTV, Esposito B, Nicolosi D, Calagna M, Nardo A, Consoli U, Uccello G, Di Giacomo V, Neri S, Cingari MR, Rodà F, Innao V, Fiumara A, Duro G, Zizzo C, Di Raimondo F.
Giuffrida G, et al. Among authors: nardo a.
Eur J Haematol. 2023 Dec;111(6):922-929. doi: 10.1111/ejh.14105. Epub 2023 Sep 25.
Eur J Haematol. 2023.
PMID: 37747757
Item in Clipboard
AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib.
Duminuco A, Mosquera-Orgueira A, Nardo A, Di Raimondo F, Palumbo GA.
Duminuco A, et al. Among authors: nardo a.
Cancer Rep (Hoboken). 2023 Oct;6(10):e1881. doi: 10.1002/cnr2.1881. Epub 2023 Aug 8.
Cancer Rep (Hoboken). 2023.
PMID: 37553891
Free PMC article.
Item in Clipboard
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point?
Duminuco A, Nardo A, Palumbo GA.
Duminuco A, et al. Among authors: nardo a.
Hematol Oncol. 2024 Mar;42(2):e3259. doi: 10.1002/hon.3259.
Hematol Oncol. 2024.
PMID: 38402568
No abstract available.
Item in Clipboard
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting.
Duminuco A, Nardo A, Garibaldi B, Vetro C, Longo A, Giallongo C, Di Raimondo F, Palumbo GA.
Duminuco A, et al. Among authors: nardo a.
J Clin Med. 2022 Dec 14;11(24):7418. doi: 10.3390/jcm11247418.
J Clin Med. 2022.
PMID: 36556033
Free PMC article.
Item in Clipboard
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data.
Gozzo L, Nardo A, Brancati S, Judica A, Duminuco A, Maugeri C, Parisi M, Longo L, Vitale DC, Ruscica R, Romano GL, Mauro E, Fiumara PF, Palumbo GAM, Di Raimondo F, Vetro C, Drago F.
Gozzo L, et al. Among authors: nardo a.
Healthcare (Basel). 2023 May 18;11(10):1479. doi: 10.3390/healthcare11101479.
Healthcare (Basel). 2023.
PMID: 37239765
Free PMC article.
Item in Clipboard
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions.
Duminuco A, Nardo A, Orofino A, Giunta G, Conticello C, Del Fabro V, Chiarenza A, Parisi MS, Figuera A, Leotta S, Milone G, Cupri A, Cambria D, Di Raimondo F, Romano A, Palumbo GA.
Duminuco A, et al. Among authors: nardo a.
Cancer. 2024 Jan 1;130(1):41-50. doi: 10.1002/cncr.35005. Epub 2023 Sep 1.
Cancer. 2024.
PMID: 37658645
Item in Clipboard
Cite
Cite